Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly and Company (NYSE: LLY) launched the Life Doesn't Slow Down campaign with comedian Leanne Morgan for its weight-management medicine Foundayo.
Morgan is a paid Lilly spokesperson and Foundayo patient. The campaign encourages conversations with healthcare providers about weight-management options. Foundayo (orforglipron) is a once-daily prescription pill approved by the FDA in April 2026. It is used with a reduced-calorie diet and increased physical activity for adults with obesity, or some adults with overweight and weight-related medical problems.
Eligible commercially insured patients may pay as little as $25 per month with a savings card. The self-pay option starts at $149 per month for the lowest dose, subject to eligibility and terms. Eligible Medicare Part D beneficiaries may obtain it for $50 per month through the Medicare GLP-1 Bridge program.
Eli Lilly and Company (NYSE: LLY) reported that Foundayo met the primary endpoint in its Phase 3 obstructive sleep apnea program. ATTAIN-OSA studied adults with moderate-to-severe obstructive sleep apnea and obesity or overweight over 52 weeks. Breathing interruptions fell by 21.1 events per hour without positive airway pressure (PAP) therapy and 18.3 with PAP, versus 4.3 and 5.5 with placebo. Remission or mild disease occurred in 31.5% and 19.6% of Foundayo participants, respectively.
Foundayo also reduced oxygen deprivation during sleep, weight, inflammation and systolic blood pressure. Adverse-event discontinuations were 12.2% versus 3.8% with placebo without PAP, and 6.8% versus 0.6% with PAP. Lilly plans to submit Foundayo for U.S. FDA approval for this population by the end of 2026. Results estimate efficacy assuming participants remained on treatment under specified conditions.
Eli Lilly (LLY) and Hims & Hers Health (HIMS) announced an agreement to offer Lilly’s obesity medicines through the Hims & Hers platform. Eligible patients prescribed Zepbound (tirzepatide) or Foundayo (orforglipron) can access the same self-pay prices available to any patient without leaving the platform. Prices start at $149 per month for Foundayo and $299 per month for Zepbound, with medicines shipped directly to patients’ homes.
Hims & Hers has committed not to offer compounded copies of Lilly’s GLP-1 medicines. Both companies also committed to protecting independent clinical decisions, with providers determining the appropriate treatment for each patient.
Eli Lilly and Company (NYSE: LLY) will present Phase 3 retatrutide results and Taltz–Zepbound combination data at ACR Convergence 2026. The meeting runs Nov. 6–11 in Orlando. In the 68-week TRIUMPH-4 trial, investigational retatrutide reduced knee osteoarthritis pain by up to an average of 4.5 points (75.8%) from an average baseline of 6.0. In the 80-week TRIUMPH-1 trial, pain fell by up to 4.3 points (73.1%) from a baseline of 6.0. Both used the WOMAC pain scale, a measure of osteoarthritis symptoms.
In the Phase 3b TOGETHER-PsA study, 43.7% receiving Taltz plus Zepbound achieved ACR50, a measure of improvement in psoriatic arthritis, at Week 52, versus 15.7% receiving Taltz alone. The combination study involved adults with psoriatic arthritis and obesity or overweight with at least one weight-related condition.
Mastercard (MA) reported third-quarter net revenue growth of 14% to $9.8 billion, alongside higher earnings across several other large companies.
Mastercard diluted EPS rose to $5.28 from $4.34 a year earlier. Lilly (LLY) revenue increased 39% to $24.4 billion, and its 2026 revenue outlook rose to $91.0 billion–$92.0 billion. Caterpillar (CAT) sales and revenues increased 17% to $20.7 billion, with operating margin reaching 20.4%. Arista Networks (ANET) revenue rose 58.5% to approximately $3.66 billion; it expects fourth-quarter revenue of $3.9 billion–$4.0 billion. ADM (ADM) raised its 2026 adjusted EPS guidance to approximately $5.50–$5.80.
Treasury's quarterly refunding details and September trade data are scheduled for 8:30 a.m. ET. Treasury expects October–December borrowing of $618 billion, assuming an end-of-December cash balance of $850 billion.
Eli Lilly and Company (LLY) reported third-quarter 2026 revenue of $24.4 billion, driven primarily by Mounjaro and Zepbound sales. Revenue rose 39% year over year, while reported earnings per share increased 16% to $7.22. Revenue included approximately $900 million of benefits from milestones and rebate and discount estimate adjustments.
Lilly raised its 2026 revenue outlook to $91–$92 billion from $85–$87 billion. Non-GAAP EPS guidance fell to $35.00–$36.00 from $35.50–$36.50: a $4.07 underlying midpoint increase was more than offset by $4.57 in acquired in-process research and development charges. FDA approvals covered Mounjaro cardiovascular risk reduction, Onswik, Inluriyo with Verzenio, and expanded Jaypirca and Olumiant indications. Lilly reported positive retatrutide, Ebglyss and EloraTZP trial results, completed the AtaiBeckley acquisition during the quarter and acquired Merida Biosciences after quarter-end.
Eli Lilly and Company (LLY) reported that retatrutide met the primary and all key secondary endpoints in Phase 3 TRANSCEND-T2D-2. The trial compared retatrutide with injectable Ozempic 2 mg in 1,298 adults with type 2 diabetes. At 80 weeks, retatrutide 9 mg and 12 mg each reduced A1C, a measure of blood sugar, by 2.2% versus 1.8% with Ozempic. Average weight loss was 44.3 lbs (19.5%) and 47.4 lbs (20.9%), respectively, versus 20.9 lbs (9.4%).
Adverse-event discontinuation rates were 4.8% and 7.9% with retatrutide versus 2.7% with Ozempic. Most reported adverse events were mild-to-moderate and typically resolved during treatment. Results use an analysis assuming participants remained on treatment without additional blood-sugar medication for more than 14 days. Retatrutide remains investigational; detailed results are planned for a medical meeting and peer-reviewed publication.
Eli Lilly and Company (LLY) announced that international president Patrik Jonsson will retire at the end of 2026 after 36 years.
Effective Jan. 1, 2027, Lilly will combine its U.S. and international businesses into Lilly Global Markets. Ilya Yuffa will become executive vice president and president of the organization, overseeing customer strategy and execution worldwide. Lilly expects the consolidation to accelerate decision-making and increase scalability.
Laura Steele will be promoted to president, Lilly USA, and Elias Khalil to group vice president and president, Lilly Europe and Canada. They will join the leaders of the other four geographic hubs in reporting to Yuffa.
Eli Lilly (LLY) declared a fourth-quarter 2026 dividend of $1.73 per share on its outstanding common stock. The dividend is payable on December 10, 2026, to shareholders of record at the close of business on November 13, 2026.
Eli Lilly and Company (NYSE: LLY) presented updated olomorasib combination results for first-line KRAS G12C-mutant non-small cell lung cancer at ESMO 2026.
Among 85 patients receiving olomorasib plus pembrolizumab without chemotherapy, median response duration and progression-free survival, the time without disease worsening, were not reached after median follow-up of 20.7 months. In a separate single-arm analysis of 77 patients receiving olomorasib plus pembrolizumab and chemotherapy, the investigator-assessed confirmed response rate was 62%, median response duration was 14.5 months and median progression-free survival was 11.6 months. Treatment-related adverse events led to regimen discontinuation in 11.8% and 7.8%, respectively; neither group had fatal treatment-related events. Lilly expects the first randomized Phase 3 SUNRAY-01 results in the first half of 2027. Part B has completed enrollment.